'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
about
'DURVIT': a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment
description
im September 2018 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 12 September 2018
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована у вересні 2018
@uk
name
'DURVIT': a phase-I trial of s ...... nd lymph node microenvironment
@en
'DURVIT': a phase-I trial of s ...... nd lymph node microenvironment
@nl
type
label
'DURVIT': a phase-I trial of s ...... nd lymph node microenvironment
@en
'DURVIT': a phase-I trial of s ...... nd lymph node microenvironment
@nl
prefLabel
'DURVIT': a phase-I trial of s ...... nd lymph node microenvironment
@en
'DURVIT': a phase-I trial of s ...... nd lymph node microenvironment
@nl
P2093
P2860
P1433
P1476
'DURVIT': a phase-I trial of s ...... nd lymph node microenvironment
@en
P2093
E S Jordanova
G G Kenter
T D de Gruijl
P2860
P2888
P356
10.1186/S12885-018-4764-0
P407
P577
2018-09-12T00:00:00Z
P6179
1106942538